# Brainomix

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/brainomix

- Industry: Software
- Headquarters: Oxford, UK
- Website: www.brainomix.com
- Total disclosed funding: $51M
- Latest round: Series C (Feb 13, 2026)
- Investors on record: 8

## About

Based in the UK, Brainomix Limited pioneers AI-driven imaging solutions that enhance clinical decision-making and patient outcomes, specifically in stroke, interstitial lung disease, and solid tumors.Brainomix Limited, founded in 2010 and headquartered in Oxford, UK, specializes in AI imaging solutions to improve healthcare. The company was co-founded by Andrew Barker, Constantin Thiopoulos, Med Grunwald, Michael Printzos, and Michalis Papadakis, who currently serves as CEO. In February 2026, Brainomix Limited raised GBP 4.8 million in series C funding co-led by Parkwalk Advisors and Hostplus, with participation from Modi Ventures. The round was part of a larger GBP 18.8 million series C funding. Brainomix specializes in the development of AI-powered imaging solutions aimed at enhancing clinical decision-making and patient outcomes in various therapeutic areas, primarily focused on stroke, interstitial lung disease (ILD), and solid tumors. The company's flagship product, the Brainomix 360 Stroke platform, automates validated imaging biomarkers to facilitate rapid and accurate stroke assessment, allowing healthcare providers to make informed treatment decisions. Additionally, Brainomix offers the e-Lung platform, designed for the assessment of ILD, and a solid tumor assessment solution, which includes a comprehensive set of classifiers and biomarkers tailored for use in clinical trials for conditions like non-small cell lung cancer (NSCLC). These products are utilized by healthcare systems globally, with significant adoption noted in markets such as the United Kingdom, United States, and various countries across Europe and Asia, all aimed at addressing unmet clinical needs and improving patient care.Brainomix generates revenue primarily through subscription-based models and partnerships with healthcare institutions and research organizations. Transactions typically involve licensing their AI imaging solutions to hospitals and clinical trial sponsors, enabling them to enhance diagnostic accuracy and treatment planning. The company's offerings, such as the Brainomix 360 Stroke and e-Lung platforms, operate under structured pricing plans that reflect the value of automated imaging capabilities in clinical settings. These partnerships may also include collaborative agreements for joint research and development initiatives, further solidifying Brainomix's position in the healthcare market. The EBITDA for the most recent year, 2022, is reported at GBP 0. The company plans to use the February 2026 funding to expand its U.S. operations, deploy its Brainomix 360 Stroke and e-Lung platforms across more hospitals, and strengthen customer support and product development.

## Funding rounds

- Series C, Feb 13, 2026, $6.5M — Hostplus, Parkwalk Advisors, Modi Ventures
- Series C, Dec 13, 2024, $24M — Longview Innovation, Boehringer Ingelheim Venture, Parkwalk Advisors, LifeSci Capital LLC
- Series B, Dec 3, 2021, $21M — Boehringer Ingelheim Venture, Parkwalk Advisors, Tencent Holdings Limited, Oxford University Innovation Limited

## Investors

- Boehringer Ingelheim Venture (https://capitalatlas.ai/funds/boehringer-ingelheim-venture) — Series B, Series C
- Parkwalk Advisors (https://capitalatlas.ai/funds/parkwalk-advisors) — Series B, Series C
- Tencent Holdings Limited — Series B
- Oxford University Innovation Limited — Series B
- Longview Innovation (https://capitalatlas.ai/funds/longview-innovation) — Series C
- LifeSci Capital LLC — Series C
- Hostplus — Series C
- Modi Ventures (https://capitalatlas.ai/funds/modi-ventures) — Series C